Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Bone density and alendronate effects in Duchenne muscular dystrophy patients.

Houston C, Mathews K, Shibli-Rahhal A.

Muscle Nerve. 2014 Apr;49(4):506-11. doi: 10.1002/mus.23948. Epub 2014 Feb 10.

PMID:
23835890
2.

Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.

Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD.

Arch Phys Med Rehabil. 2005 Feb;86(2):284-8.

PMID:
15706555
3.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
4.

Skeletal health in Duchenne dystrophy: bone-size and subcranial dual-energy X-ray absorptiometry analyses.

King WM, Kissel JT, Visy D, Goel PK, Matkovic V.

Muscle Nerve. 2014 Apr;49(4):512-9. doi: 10.1002/mus.23963. Epub 2014 Feb 26.

PMID:
23893858
5.

The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.

Rheumatol Int. 2005 Nov;26(1):21-9. Epub 2005 Feb 2.

PMID:
15688191
6.

Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.

Apkon S, Coll J.

Am J Phys Med Rehabil. 2008 Feb;87(2):139-43.

PMID:
17912140
7.

Randomized controlled trial of alendronate in airways disease and low bone mineral density.

Smith BJ, Laslett LL, Pile KD, Phillips PJ, Phillipov G, Evans SM, Esterman AJ, Berry JG.

Chron Respir Dis. 2004;1(3):131-7.

PMID:
16281654
8.

Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).

Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D; ANRS 120 Fosivir Study Group.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):972-80. Epub 2012 Mar 23.

PMID:
22353022
9.

Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease.

Tsujikawa T, Andoh A, Inatomi O, Bamba S, Nakahara T, Sasaki M, Saito H, Fujiyama Y.

Intern Med. 2009;48(12):933-7. Epub 2009 Jun 15.

10.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

11.

Effect of alendronate on bone mineral density in male idiopathic osteoporosis.

Weber TJ, Drezner MK.

Metabolism. 2001 Aug;50(8):912-5.

PMID:
11474478
12.

Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.

Geller JL, Hu B, Reed S, Mirocha J, Adams JS.

Endocr Pract. 2008 Apr;14(3):293-7.

PMID:
18463035
13.

Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.

Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:144-8.

PMID:
19337169
14.

The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.

Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM.

Osteoporos Int. 2012 Nov;23(11):2703-11.

PMID:
22297733
15.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

16.

Bone mineral density and bone metabolism in Duchenne muscular dystrophy.

Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, Morandi L.

Osteoporos Int. 2003 Sep;14(9):761-7. Epub 2003 Jul 29.

PMID:
12897980
17.

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.

AIDS. 2007 Nov 30;21(18):2473-82.

PMID:
18025884
18.

Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.

Ringe JD, Dorst A, Farahmand P.

Arzneimittelforschung. 2010;60(5):267-72.

PMID:
20533764
19.

Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy.

Söderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, Swolin-Eide D.

Neuromuscul Disord. 2007 Dec;17(11-12):919-28. Epub 2007 Jul 12.

PMID:
17627820
20.

Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis.

Martinó A, Rosa J, Guzmán J, Ramírez M.

P R Health Sci J. 2005 Jun;24(2):131-5.

PMID:
16116930
Items per page

Supplemental Content

Write to the Help Desk